tiprankstipranks
Enovis (DE:C520)
FRANKFURT:C520
Germany Market
C520
Enovis
RESEARCH TOOLSreports

Enovis (C520) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

C520 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Enovis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

C520 Stock 12 Month Forecast

Average Price Target

€35.65
▲(57.73% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is €35.65 with a high forecast of €45.09 and a low forecast of €25.15. The average price target represents a 57.73% change from the last price of €22.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","31":"€31","46":"€46","23.5":"€23.5","38.5":"€38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45.08972832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€45.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.647862133333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€35.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.146194639999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,23.5,31,38.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.4,26.914594486153845,28.429188972307692,29.94378345846154,31.458377944615386,32.97297243076923,34.48756691692307,36.002161403076926,37.516755889230765,39.03135037538462,40.54594486153846,42.06053934769231,43.57513383384615,{"y":45.08972832,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.4,26.188297087179485,26.976594174358972,27.76489126153846,28.55318834871795,29.341485435897436,30.129782523076923,30.91807961025641,31.706376697435896,32.49467378461539,33.28297087179487,34.07126795897436,34.85956504615385,{"y":35.647862133333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.4,25.380476510769228,25.36095302153846,25.34142953230769,25.321906043076922,25.30238255384615,25.282859064615383,25.263335575384612,25.243812086153845,25.224288596923074,25.204765107692307,25.185241618461536,25.16571812923077,{"y":25.146194639999997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€45.09Average Price Target€35.65Lowest Price Target€25.15
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:C520
Patrick Wood
UBS
UBS
€43.36→€44.22
Buy
95.68%
Upside
Initiated
07/28/26
Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS
Jefferies Analyst forecast on DE:C520
Rong Li
Jefferies
Jefferies
€34.68
Buy
53.47%
Upside
Reiterated
07/14/26
Enovis (ENOV) Receives a Buy from Jefferies
BMO Capital Analyst forecast on DE:C520
Vik Chopra
BMO Capital
BMO Capital
€25.15
Buy
11.27%
Upside
Initiated
07/09/26
Enovis initiated with an Outperform at BMO CapitalEnovis initiated with an Outperform at BMO Capital
Evercore ISI Analyst forecast on DE:C520
Vijay Kumar
Evercore ISI
Evercore ISI
€31.22→€27.75
Buy
22.78%
Upside
Reiterated
07/06/26
Enovis price target lowered to $32 from $36 at Evercore ISIEnovis price target lowered to $32 from $36 at Evercore ISI
BTIG Analyst forecast on DE:C520
Ryan Zimmerman
BTIG
BTIG
€33.82
Buy
49.63%
Upside
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP) and Enovis (NYSE: ENOV)
Needham Analyst forecast on DE:C520
Michael Matson
Needham
Needham
€45.09
Buy
99.51%
Upside
Reiterated
05/18/26
Enovis: Buy Rating Reiterated as Analyst Sees Attractive Risk-Reward, Maintains $52 Price Target Despite BGS Reclassification Risks
Canaccord Genuity Analyst forecast on DE:C520
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
€43.36
Buy
91.84%
Upside
Reiterated
05/11/26
Canaccord Genuity Keeps Their Buy Rating on Enovis (ENOV)
William Blair Analyst forecast on DE:C520
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Enovis (NYSE: ENOV) and Revelation Biosciences (NASDAQ: REVB)
Robert W. Baird Analyst forecast on DE:C520
Jeff Johnson
Robert W. Baird
Robert W. Baird
€39.02→€32.08
Buy
41.96%
Upside
Reiterated
05/08/26
Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird
Wells Fargo Analyst forecast on DE:C520
Larry Biegelsen
Wells Fargo
Wells Fargo
€36.42→€34.68
Buy
53.47%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
Freedom Capital Markets Analyst forecast on DE:C520
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
€39.02
Buy
72.65%
Upside
Initiated
12/16/25
Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets
J.P. Morgan Analyst forecast on DE:C520
Robbie Marcus
J.P. Morgan
J.P. Morgan
€28.61
Hold
26.61%
Upside
Reiterated
08/08/25
Analysts' Top Healthcare Picks: DENTSPLY SIRONA (XRAY), Replimune Group (REPL)
Roth MKM Analyst forecast on DE:C520
Jason Wittes
Roth MKM
Roth MKM
€65.03
Buy
187.76%
Upside
Reiterated
08/08/25
Enovis (ENOV) Gets a Buy from Roth MKM
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:C520
Patrick Wood
UBS
UBS
€43.36→€44.22
Buy
95.68%
Upside
Initiated
07/28/26
Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS
Jefferies Analyst forecast on DE:C520
Rong Li
Jefferies
Jefferies
€34.68
Buy
53.47%
Upside
Reiterated
07/14/26
Enovis (ENOV) Receives a Buy from Jefferies
BMO Capital Analyst forecast on DE:C520
Vik Chopra
BMO Capital
BMO Capital
€25.15
Buy
11.27%
Upside
Initiated
07/09/26
Enovis initiated with an Outperform at BMO CapitalEnovis initiated with an Outperform at BMO Capital
Evercore ISI Analyst forecast on DE:C520
Vijay Kumar
Evercore ISI
Evercore ISI
€31.22→€27.75
Buy
22.78%
Upside
Reiterated
07/06/26
Enovis price target lowered to $32 from $36 at Evercore ISIEnovis price target lowered to $32 from $36 at Evercore ISI
BTIG Analyst forecast on DE:C520
Ryan Zimmerman
BTIG
BTIG
€33.82
Buy
49.63%
Upside
Reiterated
07/06/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP) and Enovis (NYSE: ENOV)
Needham Analyst forecast on DE:C520
Michael Matson
Needham
Needham
€45.09
Buy
99.51%
Upside
Reiterated
05/18/26
Enovis: Buy Rating Reiterated as Analyst Sees Attractive Risk-Reward, Maintains $52 Price Target Despite BGS Reclassification Risks
Canaccord Genuity Analyst forecast on DE:C520
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
€43.36
Buy
91.84%
Upside
Reiterated
05/11/26
Canaccord Genuity Keeps Their Buy Rating on Enovis (ENOV)
William Blair Analyst forecast on DE:C520
Steven Lichtman
William Blair
William Blair
―
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Enovis (NYSE: ENOV) and Revelation Biosciences (NASDAQ: REVB)
Robert W. Baird Analyst forecast on DE:C520
Jeff Johnson
Robert W. Baird
Robert W. Baird
€39.02→€32.08
Buy
41.96%
Upside
Reiterated
05/08/26
Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird
Wells Fargo Analyst forecast on DE:C520
Larry Biegelsen
Wells Fargo
Wells Fargo
€36.42→€34.68
Buy
53.47%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
Freedom Capital Markets Analyst forecast on DE:C520
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
€39.02
Buy
72.65%
Upside
Initiated
12/16/25
Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets
J.P. Morgan Analyst forecast on DE:C520
Robbie Marcus
J.P. Morgan
J.P. Morgan
€28.61
Hold
26.61%
Upside
Reiterated
08/08/25
Analysts' Top Healthcare Picks: DENTSPLY SIRONA (XRAY), Replimune Group (REPL)
Roth MKM Analyst forecast on DE:C520
Jason Wittes
Roth MKM
Roth MKM
€65.03
Buy
187.76%
Upside
Reiterated
08/08/25
Enovis (ENOV) Gets a Buy from Roth MKM
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enovis

3 Months
Jeff JohnsonRobert W. Baird
Success Rate
6/15 ratings generated profit
40%
Average Return
-1.55%
Copying Jeff Johnson's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -1.55% per trade.
1 Year
Vijay KumarEvercore ISI
Success Rate
7/13 ratings generated profit
54%
Average Return
-4.02%
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -4.02% per trade.
2 Years
Vijay KumarEvercore ISI
Success Rate
5/13 ratings generated profit
38%
Average Return
-10.21%
Copying Vijay Kumar's trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of -10.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

C520 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
8
10
9
9
4
Buy
1
4
4
5
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
14
13
14
6
In the current month, C520 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. C520 average Analyst price target in the past 3 months is 35.65.
Each month's total comprises the sum of three months' worth of ratings.

C520 Financial Forecast

C520 Earnings Forecast

Next quarter’s earnings estimate for C520 is €0.74 with a range of €0.69 to €0.78. The previous quarter’s EPS was €0.77. C520 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.94% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.
Next quarter’s earnings estimate for C520 is €0.74 with a range of €0.69 to €0.78. The previous quarter’s EPS was €0.77. C520 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.94% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.

C520 Sales Forecast

Next quarter’s sales forecast for C520 is €505.38M with a range of €500.31M to €508.99M. The previous quarter’s sales results were €511.73M. C520 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.50% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.
Next quarter’s sales forecast for C520 is €505.38M with a range of €500.31M to €508.99M. The previous quarter’s sales results were €511.73M. C520 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.50% of the time in the same period. In the last calendar year C520 has Performed in-line its overall industry.

C520 Stock Forecast FAQ

What is DE:C520’s average 12-month price target, according to analysts?
Based on analyst ratings, Enovis’s 12-month average price target is 35.65.
    What is DE:C520’s upside potential, based on the analysts’ average price target?
    Enovis has 57.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Enovis a Buy, Sell or Hold?
          Enovis has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Enovis’s share price target?
            The average share price target for Enovis is 35.65. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €45.09 ,and the lowest forecast is €25.15. The average share price target represents 57.73% Increase from the current price of €22.6.
              What do analysts say about Enovis?
              Enovis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Enovis?
                To buy shares of DE:C520, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.